Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00596830 |
Determine whether the addition of CP 751,871 in combination with paclitaxel plus carboplatin prolongs survival in patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV or recurrent) NSCLC of non adenocarcinoma histology.
Condition | Intervention | Phase |
---|---|---|
Carcinoma, Squamous Cell Carcinoma, Adenosquamous Carcinoma, Large Cell Carcinoma, Non-Small-Cell Lung |
Drug: CP-751,871 + Carboplatin +Paclitaxel Drug: Carboplatin + Paclitaxel |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Randomized, Open Label, Phase III Trial Of CP- 751,871 In Combination With Paclitaxel And Carboplatin Versus Paclitaxel And Carboplatin In Patients With Non Small Cell Lung Cancer |
Estimated Enrollment: | 820 |
Study Start Date: | March 2008 |
Estimated Study Completion Date: | July 2011 |
Estimated Primary Completion Date: | July 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Experimental
Patients in Arm A will receive CP-751, 871 in combination with paclitaxel and carboplatin intravenously every 21 days for up to six cycles.`
|
Drug: CP-751,871 + Carboplatin +Paclitaxel
CP 751,871 is a potent and selective fully human monoclonal antibody against the insulin like growth factor 1 receptor (IGF-1R). Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. |
B: Active Comparator
Patient in Arm B will receive paclitaxel and carboplatin intravenously every 21 days for up to six cycles.
|
Drug: Carboplatin + Paclitaxel
Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Pfizer Oncology Clinical Trial Information Service | 1-877-369-9753 | PfizerCancerTrials@emergingmed.com |
Contact: Pfizer CT.gov Call Center | 1-800-718-1021 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A4021016 |
Study First Received: | January 3, 2008 |
Last Updated: | September 3, 2009 |
ClinicalTrials.gov Identifier: | NCT00596830 History of Changes |
Health Authority: | United States: Food and Drug Administration |
IGF-1R inhibitor, Non-small-cell lung carcinoma, CP-751871 |
Thoracic Neoplasms Antimitotic Agents Carboplatin Insulin Carcinoma Antibodies, Monoclonal Antibodies Respiratory Tract Diseases Lung Neoplasms Paclitaxel Lung Diseases |
Tubulin Modulators Carcinoma, Large Cell Mitogens Non-small Cell Lung Cancer Neoplasms, Squamous Cell Carcinoma, Squamous Cell Antineoplastic Agents, Phytogenic Carcinoma, Non-Small-Cell Lung Carcinoma, Adenosquamous Immunoglobulins Neoplasms, Glandular and Epithelial |
Thoracic Neoplasms Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Neoplasms by Site Respiratory Tract Diseases Lung Neoplasms Therapeutic Uses Neoplasms, Squamous Cell Respiratory Tract Neoplasms Neoplasms by Histologic Type Mitosis Modulators Carboplatin Antimitotic Agents |
Pharmacologic Actions Carcinoma Neoplasms Paclitaxel Lung Diseases Carcinoma, Large Cell Tubulin Modulators Carcinoma, Squamous Cell Antineoplastic Agents, Phytogenic Carcinoma, Adenosquamous Carcinoma, Non-Small-Cell Lung Neoplasms, Complex and Mixed Neoplasms, Glandular and Epithelial |